

Evonik is streamlining processes and reducing administrative and selling expenses

- Next step towards a performance-oriented corporate culture with a healthy cost structure
- Up to 1,000 jobs to be cut worldwide in administration and sales by year-end 2020
- · Agreement with employee representatives on key points

Essen. Evonik is reducing bureaucracy, streamlining processes, and cutting administrative and selling expenses. To achieve the target of permanently reducing the cost base by \in 200 million by the end of 2020, management and employee representatives have agreed on key points. The associated analysis of all administrative and sales functions has been completed.

"Our goal is to build a best-in-class specialty chemicals company," said Christian Kullmann, Chairman of Evonik's Board of Management. "To get there we need three things: a balanced portfolio, leading innovative capability, and a new, performanceoriented corporate culture. To this end, we are now making a big step forward on the cost side. We want to accelerate decisionmaking and strengthen cost-awareness."

In fall 2017, Evonik set itself the target of permanently reducing administrative and selling expenses by €200 million worldwide. About two-thirds of the cost savings will come from administration and a third will come from sales functions.

The first \in 50 million of these permanent savings will be achieved this year and will mainly comprise material costs. To realize the remaining \in 150 million, a detailed analysis of all administrative support functions was carried out in recent months.

As a result of this analysis, up to 1,000 jobs will be cut in administration and sales by the end of 2020. Management and employee representatives have agreed to implement the process in a socially acceptable manner. The agreement that rules out business-related dismissals for employees in Germany has been extended until mid-2023. Evonik will also be using natural June 27, 2018

Matthias Ruch External Communications Phone +49 201 177-3348 Matthias.Ruch@evonik.com

Evonik Industries AG

Rellinghauser Straße 1–11 45128 Essen Germany Phone +49 201 177–01 Fax +49 201 177–3475 www.evonik.com

Supervisory Board

Bernd Tönjes, Chairman Dr. Werner Müller, Honorary Chairman **Executive Board** Christian Kullmann, Chairman Dr. Harald Schwager, Deputy Chairman Thomas Wessel, Ute Wolf

Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474



fluctuation to reduce the number of jobs in administration and sales worldwide. Vacant positions will be examined to see whether it is necessary to fill them.

"Within the bounds of a policy document we will agree on important and proven social-plan instruments as well as starting with new, innovative ones," said Martin Albers, Chairman of the General Works Council. "At the same time, within this framework, we have managed to achieve the greatest possible job security for our colleagues with the ruling out of business-related dismissals for a period of five years. In doing so, the executive board, the employee representatives and the IG BCE union have demonstrated that trustworthy cooperation and a collaborative set-up can lead to success, even for difficult processes."

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.